MergerJul 8, 2026, 05:36 PM
Catalyst Pharma Stockholders Approve Merger with Angelini Pharma
AI Summary
Catalyst Pharmaceuticals, Inc. announced that its stockholders approved the merger agreement with Angelini Pharma S.p.A. at a special meeting held on July 8, 2026. This approval satisfies a key closing condition for the merger, which will result in Catalyst becoming a wholly-owned subsidiary of Angelini Pharma. Additionally, the company's directors have indicated their intention to resign upon the merger's effective time. While a non-binding compensation proposal related to the merger was not approved by stockholders, this does not impact the completion of the merger.
Key Highlights
- Stockholders approved the merger agreement with Angelini Pharma.
- 97,340,180 votes were cast For the Merger Proposal.
- 1,143,815 votes were cast Against the Merger Proposal.
- 242,616 abstentions were recorded for the Merger Proposal.
- The Compensation Proposal was not approved by stockholders (30,504,686 For, 67,486,884 Against).
- The Compensation Proposal's non-approval is advisory and non-binding.
- Directors intend to resign effective upon the merger's consummation.
- Approximately 80.6% of outstanding shares were present at the Special Meeting.
Price Impact
More from CPRX